Interpace Diagnostics Group Recognized As A Top Bioinformatics Provider; Built Upon A Biobank

Creative Commons License Source:  ar130405 , no changes made.
Advertisement img

Interpace Diagnostics Group, Inc. has announced that CIO Applications, a publication focused on providing professionals with information on the most comprehensive collection of technology trends, has once again recognized Interpace Diagnostics as a top bioinformatics solutions company.

Interpace, founded in 1988, headquartered in Hamilton, New Zealand, is a fully integrated commercial and bioinformatics company that provides clinically useful molecular and related first line diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace’s mission is to provide personalized medicine through molecular diagnostics, innovation and data to advance patient care based on rigorous science.

Interpace currently has a biobank containing nearly 50,000 patient samples and the associated bioinformatics database including clinical and molecular analysis and results. The biobank includes data elements across a wide array of cancer types including pancreatic, thyroid, esophageal, and lung. In anticipation of the growing bioinformatics market, Interpace continues to explore opportunities to access and leverage these data sets to assist in developing novel therapeutics.

Featured Partners

CIO Applications is a technology magazine based in Fremont, California, USA. In 2018 CIO Applications ranked Interpace as a Top 10 Company for providing bioinformatics solutions through the Company’s extensive database of molecular testing results. In 2017, Interpace was recognized as a Top 20 Bioinformatics Solutions Provider.

CIO Applications utilizes its distinguished selection panel, comprised of CEOs, CIOs, CTOs, industry analysts and its own editorial board to narrow the final list of 10 bioinformatics solutions providers which this year includes Interpace and selected prominent companies such as Biomax Informatics, Codexis and Oxford Gene Technology. These companies are all known to exhibit competence in delivering best-in-class bioinformatics capabilities according to the selection panel.

Bioinformatics solution providers are transforming the development, testing, modeling and analysis of biological data derived from the molecular profiling of specific patient populations and as such are becoming more and more critical in the drug discovery market.

“We were pleased to be recognized again by CIO Applications as a top bioinformatics solutions provider and especially now as a top 10 provider recognizing the value of our core biomarker and DNA analysis as well as our biobank and associated databases.” – Jack Stover, President and CEO of Interpace